期刊
TUBERCULOSIS
卷 88, 期 -, 页码 S3-S17出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/S1472-9792(08)70032-5
关键词
tuberculosis; Mycobacterium tuberculosis; drug discovery; fluoroquinolones; oxazolidinones; diarylquinolines; nitroimidazooxazoles; nitroimidazooxazines
Drug discovery and development, from an initial disease treatment concept to a new drug application (NDA), is a complex, lengthy and expensive process. In this review we discuss the key stages of drug discovery and early development, including target identification and validation, assay development and screening, confirmed hits to leads, lead optimization, and progressing development candidates to an investigational new drug (IND) filing. We also provide particular examples of how this process is beginning to assist in the development of small molecule treatments for tuberculosis, by summarizing the status of the clinical development of several newer classes of drugs. These include the fluoroquinolones, oxazolidinones, diarylquinolines, and nitroimidazooxazoles and -oxazines. (c) 2008 Elsevier Ltd. All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据